The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.

Slides:



Advertisements
Similar presentations
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Advertisements

PwC Medical Device Compliance Survey Discussion of Survey Results.
VCOM Conflict of Interest Policy Overview of Financial Conflict of Interest Related to Research December 4, 2013.
Financial Conflict of Interest July 2012 rev
2012 GEORGIA CONSERVATION PARTNERSHIP SUPERVISOR TRAINING Managing District Funds.
Conflict of Interest (COI) Objectives: Provide an overview of financial conflict of interest (FCOI) related to research activities at Gillette Describe.
HIPAA Privacy Rule Training
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
REGULATIONS ON INVESTMENT ADVISERS
Financial Conflict of Interest (FCOI) Updates Office of Sponsored Programs April 2014.
NIH FINANCIAL CONFLICT OF INTEREST REGULATIONS – 2012 Office of Sponsored Programs Research & Graduate Studies.
MSRB Proposed Rules and Interpretations NALHFA 2011 Annual Educational Conference May 20, 2011.
LITIGATION MANAGEMENT – Effective Cost Containment 2002 Conference Branson, Missouri.
CDBG Financial Management Requirements For Grant Administrators.
Mott Community College
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
House Bill 2437 Health Carrier Access Payment Commissioner Kim Holland Oklahoma Insurance Department.
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
2005 FPMP Compliance Training: Physician/Hospital Financial Arrangements Presented by: Brigid M. Maloney, Esq. Brigid M. Maloney, Esq. U.B. Associates.
Circular A-110 Everything You Didn’t Want to Know.
1 PREPARING FORM 5500 SCHEDULE C A Presentation of The Profit Sharing/401k Council of America, The Securities Industry and Financial Markets Association.
SERVICE STANDARDS Missouri Medicaid Audit and Compliance Provider Certification Review Materials.
Promoting Objectivity in Research by Managing, Reducing, or Eliminating Conflicts of Interest UT HOP UT HOP The University of Texas at Austin.
Introducing New Techniques and New Technologies: Role of the BOA Code of Ethics Gordon Bannister Professor of Orthopaedic Surgery University of Bristol.
Financial Management How Can I Spend Award Dollars.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
Legal Issues in Hospital- Hospice (and Other) Partnerships Brooke Bumpers, Esq. Hogan & Hartson, LLP Washington, D.C. October 12, 2002.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Overview OTL Mission Inventor Responsibility Stanford Royalty Sharing Disclosure Form Patent View Inventor Agreements Patent.
MassMEDIC February 26, 2010 Licensing and Compliance Presenter David L. Cavanaugh 60 State Street Boston, MA Pennsylvania Avenue, NW Washington,
Sunshine Act Clinical Faculty Meeting August 14, 2014.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
Computerized Networking of HIV Providers Workshop Data Security, Privacy and HIPAA: Focus on Privacy Joy L. Pritts, J.D. Assistant Research Professor Health.
SBIR Budgeting Leanne Robey Chief, Special Reviews Branch, NIH.
OPEN PAYMENTS UF College of Medicine Brown Bag July 23, 2013 Gary Wimsett, Jr., JD.
Communication campaign Most common issues identified: analysis per cost category Antonio Requena Fernández FCH JU Financial Officer.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
University of Pittsburgh Presentation to Schools of Pharmacy and Nursing: Consulting Requirements within the Industry Relationship Policy Presented by.
February 16, The Gift Ban Revolving Door Political Activities Ex Parte Communications.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Fight On Training on NIH Conflict of Interest Rule and Introduction to diSClose Dan Shapiro Director, Research Compliance Ben Bell Manager, Research Compliance.
+ Role of Industry in Clinical Care, Research, and Education.
Wisconsin Department of Health Services Contracting and Wis. Stat Shelley Malofsky DHS Office of Legal Counsel May 7, 2015 Wisconsin Department.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
Connolly – International Financial Accounting and Reporting – 4 th Edition CHAPTER 22 RELATED PARTY DISCLOSURES.
Discount Medical Plan Organizations (DMPOs) David Foy Florida Office of Insurance Regulation January 25, 2006.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
“Commercial Interest” ● ‘exempt’ entities (per ACCME) ● ‘exempt’ entities (per ACCME) – 501-C non-profit organizations – Government organizations – Non-health.
SMJ Life Health Annuities/Secure Benefits Alliance 2012.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
The Physician Payments Sunshine Act Legislation Ann Leopold Kaplan October 27, 2008.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
Ownership Alternatives Public Meeting Premier Healthcare Resources.
Copyright © Texas Education Agency Accounting for Grant Funds, including Documentation for Expenditures.
Modified Cash Standard Expenditure Classification
Brustein & Manasevit, PLLC
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
Analysis of the Proposed Sunshine Rule: Legal Considerations
The Importance of Subrecipient Monitoring
Compliance Program 2018.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Beyond the DOJ: Compliance Best Practices in the Orthopedic Environment.
Regional healthcare coalition match documentation
NEW SBA Form 159 Notice (a) & 504
Benchmarking Compliance for the Healthcare Industry
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas Epstein Becker & Green, PC Washington, DC

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Even though few manufacturers are subject to a DPA, all manufacturers can benefit from what these companies have been required to do and adopt best practices: 1.Understand the underlying legal issues 2.Develop policies for determining the needs in contracting with physicians/consultants 3.Develop procedures for approving and renewing such arrangements 4.Adopt process for determining fair market value 5.Maintain a database of all financial relationships 6.Have the mindset “Would we be comfortable if all our financial relationships were listed in the New York Times?” 7.Be prepared to terminate an arrangements if services are not being rendered or are no longer necessary

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Best Practice 1: Understand the underlying legal issues – The Federal Health Care Program Anti-Kickback Statute provides criminal and civil penalties for individuals and entities that knowingly and willfully offer, pay, solicit or receive remuneration in order to induce business for which payment may be made under a federal health care program. – The type of remuneration covered by the Anti-Kickback Statute includes, but is not limited to, kickbacks, bribes, and rebates. – applies to any such remuneration whether made directly or indirectly, overtly or covertly, in cash or in kind. – Moreover, prohibited conduct includes not only remuneration intended to induce referrals, but also remuneration intended to induce the purchasing, leasing, ordering, or arranging for any good, facility, service, or item paid for by a federal health care program. Social Security Act § 1128b(b), 42 U.S.C. § 1320a-7b(b)

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Best Practice 2: Develop policies for determining the needs for physicians/consultants – Recognition that the device industry is unique and is very dependent upon physicians for the advancement and development of products – Does not have to be as rigid a process as the “needs assessment” required under the DPAs, but should be a proactive (instead of reactive) process

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Key Terms in Deferred Prosecution Agreements to Keep in Mind “Consultant” is defined as any United States-based [orthopedic] surgeon, PhD, health care professional, non- physician practitioner, medical fellow, resident or student, or any employee or agent of any educational or health care organization the Company retains for any personal or professional services or compensates or remunerates in any way, directly or indirectly, for or in anticipation of personal or professional services relating to [hip and knee reconstruction and replacement]. The term Consultant shall not include accountants, auditors, attorneys, fair market value specialists, CME providers, reimbursement specialists, any nonphysician engineering or marketing consultants, or any other types of non-physician professionals or entities excluded from this definition by the Monitor upon recommendation by the Company.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress “Consulting Agreement” includes all contracts with Consultants for services to be performed on behalf of the Company. This includes, but is not limited to, agreements for compensation, payments, remuneration, honoraria, fellowships, professional meetings, speaking engagements, teaching, publications, clinical studies, fee-for-service consulting, product development and license agreements, research, and professional services agreements. The term “Consulting Agreement” also includes agreements to provide grants, donations, sponsorships and other forms of payment to medical educational organizations, medical societies and training institutions.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress “Payment” shall include any and all compensation or remuneration paid to or for the benefit of Consultants, including but not limited to payments and reimbursements for personal or professional services, any type of securities, registered or unregistered, meals, entertainment, travel, gifts, grants, honoraria, charitable contributions, donations, sponsorships, research grants, clinical studies, professional meetings, product training, medical education, research funding, product development services, in-kind services (e.g., use of aircraft), advertising, promotion, and marketing expenses or support, and royalties or other payments for transfer of documented intellectual property. Unless otherwise approved by the Monitor, the Company shall only compensate or remunerate Consultants through direct Payments made pursuant to a Consulting Agreement. The Company shall not knowingly make any Payments to Consultants indirectly, such as through distributors.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Best Practice 3: Procedures for approving (and renewing) all arrangements – All arrangements need to be in writing – Form contracts – Process for entering into arrangements needs to be independent of marketing and sales departments

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Best Practice 4: Adopt process for determining fair market value – How does one determine the fair market value for these types of services? – Should all physicians be paid equally? Is it appropriate for different specialties to receive different amounts? – What is an appropriate payment methodology? Per hour, if so, should there be a maximum number of hours per week/month? An aggregate amount per month irrespective of hours worked?

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress – What about royalty arrangements and product development fees? – How should the entity and the physician document that services were actually rendered? How specific should time records be? Should time records be a prerequisite to payment? Who should review the time records? – If compensation under the agreement is a flat dollar amount per month with the “expectation” that the physician would be performing approximately 10 hours of work a month, what should be done if the time records only reflect 5 hours of work?

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Best Practice 5: Maintain a database of financial relationships – Use of electronic tools for contract management and risk assessments – Either developed by outside vendor or “home grown” database

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Best Practice 6: Have the Mindset “Would we be comfortable if all our financial relationships were listed in the New York Times?” – At present, there is no statutory requirement that device manufacturers disclose their financial relationships with physicians, but after the orthopedic settlements and introduction of the Physician Payments Sunshine Act (S 2029), there may be momentum for creating such a requirement – Therefore, be prepared to disclose the nature of all financial relationships with physicians in the future

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Best Practice 7: Be prepared to terminate an arrangements if services are not being rendered or are no longer necessary – Necessity for there to be a process for auditing financial relationships – Again, decision to terminate needs to be separate from sales and marketing departments